Skip to content
10-K

Annual Report

ANEBULO PHARMACEUTICALS, INC. ANEB

0001493152-25-016015

← back to feed
Filed
Sep 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Sep 25, 2025 41.08M sh
Shares Diluted FY 2025 · Jun 30, 2025 33.82M sh
Shares Diluted FY 2025 · Jun 30, 2024 25.82M sh
Operating Cash Flow FY 2025 · Jun 30, 2025 −$6.35M
Operating Cash Flow FY 2025 · Jun 30, 2024 −$8.09M
Cash And Equivalents FY 2025 · Jun 30, 2025 $11.63M
Cash And Equivalents FY 2025 · Jun 30, 2024 $3.09M
Stockholders Equity FY 2025 · Jun 30, 2025 $11.66M
Stockholders Equity FY 2025 · Jun 30, 2024 $3.81M
Stockholders Equity FY 2025 · Jun 30, 2023 $10.6M
Total Liabilities FY 2025 · Jun 30, 2025 $487.69K
Total Liabilities FY 2025 · Jun 30, 2024 $260.58K
Current Assets FY 2025 · Jun 30, 2025 $11.96M
Current Assets FY 2025 · Jun 30, 2024 $3.51M
Total Assets FY 2025 · Jun 30, 2025 $12.15M
Total Assets FY 2025 · Jun 30, 2024 $4.07M
Eps Diluted FY 2025 · Jun 30, 2025 −$0.25
Eps Diluted FY 2025 · Jun 30, 2024 −$0.32
Eps Basic FY 2025 · Jun 30, 2025 −$0.25
Eps Basic FY 2025 · Jun 30, 2024 −$0.32
Sga Expense FY 2025 · Jun 30, 2025 $4.92M
Sga Expense FY 2025 · Jun 30, 2024 $4.76M
Rd Expense FY 2025 · Jun 30, 2025 $4.3M
Rd Expense FY 2025 · Jun 30, 2024 $3.55M
Net Income FY 2025 · Jun 30, 2025 −$8.48M
Net Income FY 2025 · Jun 30, 2024 −$8.2M
Operating Income FY 2025 · Jun 30, 2025 −$9.22M
Operating Income FY 2025 · Jun 30, 2024 −$8.31M